SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing increased investor engagement as the community reacts to a series of strategic partnerships with automotive leaders and optimistic long-term growth projections for its QNX platform. Investors are actively debating the potential for a technical breakout ahead of upcoming fiscal earnings and backlog updates, with many highlighting the stock's transition from hardware to a software-centric model.

why is this coin going up? lol maybe because its created by an anon kol, just like satoshi 😉

Anoncoin

The community is rallying behind ANONCOIN, highlighting its unique protocol features and Web3 infrastructure potential as a reliable alternative to traditional memecoins. Investors are actively debating the token's scalability and its emergence as a distinct player within the broader decentralized data ecosystem.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as essential infrastructure for the DeFi sector, bolstered by high-profile institutional partnerships and its integration into the Real World Asset (RWA) narrative. The community is actively discussing the protocol's recent government collaborations, revenue-backed token buyback program, and institutional-grade data feeds as key differentiators from speculative projects.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending as the market evaluates its role as a regulated, institutional-grade stablecoin amid legislative debates like the CLARITY Act and the rising adoption of stablecoins for cross-border settlements. Investors are closely monitoring how regulatory clarity and increased competition from new payment rails impact the long-term utility and yield-bearing potential of USDC within the broader crypto ecosystem.

Pump.fun

Pump.fun is actively trending as traders debate the platform's high-volume meme coin ecosystem and its controversial reputation, with community members heavily divided between those seeking massive gains and others warning of widespread scams. Investors are simultaneously flooding discussion boards to promote emerging microcap alternatives and specific tokens, highlighting the intense, high-risk environment currently dominating the Solana network.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently under intense community scrutiny following a major $280 million exploit on the Drift Protocol, fueling debates over network security and the broader risks of DeFi. While some investors remain bullish on its ecosystem momentum and institutional partnerships, the price action has seen significant volatility as traders weigh technical stability against concerns about platform reliability.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining significant attention from investors who believe the project is uniquely positioned due to its connection to AI-driven wealth generation and its ties to the Bankr ecosystem on Base. Community members are actively sharing their bullish sentiment and discussing the token as a high-potential "sleeper" opportunity, driven by narratives surrounding Grok's reported financial activity.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE is trending as the community highlights its origin as the AI-inspired 'Grok dog' that Elon Musks AI would supposedly name. Investors are bullish on its deflationary tokenomics and persistent pack-mentality community, viewing the current market activity as a key accumulation phase before potential long-term gains in the AI meme sector.

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is trending as investors monitor the upcoming mid-2026 Phase 3 readouts for its lead candidate, Duravyu, while actively debating its competitive positioning against Ocular Therapeutix. The community is focused on analyzing trial design differences and potential market share outcomes, with high institutional ownership providing a backdrop to the ongoing discussion.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

SHLD is trending as investors capitalize on surging global defense budgets and persistent geopolitical instability, with the community actively comparing its unique exposure to both domestic military tech and international firms like Rheinmetall. Supporters view the ETF as a strategic long-term play, often contrasting its performance against traditional aerospace indices while debating the impact of increased military spending on its price trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Positive Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...

Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...

Noble Financial Has Positive Forecast for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive...

<ul class="summary-bullets"><li>The FDA is expected to decide on the application by June 29, as per the company.&nbsp;</li><li>The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.&nbsp;</li><li>The company is now looking to launch OLC in the third quarter.</li></ul>Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% on Wednesday as retail investors contemplated the possibility of approval for the company’s Oxylanthanum carbonate.UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection. The FDA is expected to decide on the application by June 29, as per the company.The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.The company is now looking to launch OLC in the third quarter and is continuing to strengthen its commercial infrastructure and advance market readiness initiatives in the meantime.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around UNCY jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Over the past week, message volume rose 150%, according to Stocktwits data.A Stocktwits user predicted revenue of as much as $600 million for OLC in 2029.<stembedurl>https://www.stocktwits.com/Thrasher5699/message/649190093</stembedurl>Yet another sees 80% chances for the drug’s approval this time.<stembedurl>https://www.stocktwits.com/Cvfiore2001/message/649096819</stembedurl><h2 class="st-heading-2">Unicycive Therapeutics Inc Management Commentary</h2>“This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration’s acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,” said CEO Shalabh Gupta earlier this week. “With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.”Hyperphosphatemia is a condition characterized by excessively high levels of phosphate in the blood.<a href="https://stocktwits.com/symbol/UNCY">UNCY stock </a>has gained nearly 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-rallies-on-much-awaited-fda-approval-for-weight-loss-pill/cZ7Hp5ORIF5">LLY Stock Rallies On Much Awaited FDA Approval For Weight Loss Pill</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.<div class="st-video-embed" data-video-url="https://videos.stocktwits-cdn.com/hls/2026/03/26/69ee8298-8c28-42e1-b686-43e84dc29610/fq6gh7vs9vzzy7rkkx2fll5vlsu3_download.mp4" data-thumbnail-url="" data-caption="" data-summary="" data-width="" data-height="" data-orientation="horizontal" data-duration="">&nbsp;</div>

Rising stock market chart on a trading board background.

UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 

Equity

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 


Noble Financial Brokers Boost Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at Noble Financial increased their Q3 2026 earnings per share estimates for Unicycive Therapeutics in a research report...

Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) released its earnings results on Monday. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates...

Unicycive Therapeutics (UNCY) to Release Quarterly Earnings on Monday

Unicycive Therapeutics (NASDAQ:UNCY) will be releasing earnings before the market opens on Monday, March 30. (View Earnings Report at...

Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 0.4% - Here's Why

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 0.4% - Should You Sell...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five brokerages that are currently covering the firm...

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4% - Should You Buy?

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4% - Still a Buy...

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

UNCY
Unicycive Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest UNCY News

UNCYUnicycive Therapeutics Inc